Better Therapeutics (Better Therapeutics) EV-to-EBIT : -0.28 (As of May. 19, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Better Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Better Therapeutics's Enterprise Value is $8.32 Mil. Better Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-29.61 Mil. Therefore, Better Therapeutics's EV-to-EBIT for today is -0.28.

The historical rank and industry rank for Better Therapeutics's EV-to-EBIT or its related term are showing as below:

BTTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -43.7 Med: 0 Max: 0.48
Current: -0.28

During the past 4 years, the highest EV-to-EBIT of Better Therapeutics was 0.48. The lowest was -43.70. And the median was 0.00.

BTTX's EV-to-EBIT is ranked worse than
100% of 426 companies
in the Biotechnology industry
Industry Median: 10.22 vs BTTX: -0.28

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Better Therapeutics's Enterprise Value for the quarter that ended in Sep. 2023 was $22.56 Mil. Better Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-29.61 Mil. Better Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -131.26%.

Better Therapeutics EV-to-EBIT Historical Data

The historical data trend for Better Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Better Therapeutics EV-to-EBIT Chart

Better Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

EV-to-EBIT

-1.95

-0.67

Better Therapeutics Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EV-to-EBIT	Get a 7-Day Free Trial									-0.79	-0.67	-0.67	-1.20	-0.76

Competitive Comparison of Better Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Better Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Better Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Better Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Better Therapeutics's EV-to-EBIT falls into.

Better Therapeutics EV-to-EBIT Calculation

Better Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	8.317	/	-29.613
	=	-0.28

Better Therapeutics's current Enterprise Value is $8.32 Mil.
Better Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-29.61 Mil.

Better Therapeutics (OTCPK:BTTX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Better Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 )	=	EBIT	/	Enterprise Value (Q: Sep. 2023 )
	=	-29.613	/	22.560548
	=	-131.26 %

Better Therapeutics's Enterprise Value for the quarter that ended in Sep. 2023 was $22.56 Mil.
Better Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-29.61 Mil.

Better Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Better Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Better Therapeutics (Better Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Better Therapeutics Inc (OTCPK:BTTX) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

548 Market Street, Suite 49404, San Francisco, CA, USA, 94104

Website

https://www.bettertx.com

Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions.

Executives

Elder Granger	director	5176 S. LEWISTON WAY, CENTENNIAL CO 80015
Mark A. Berman	officer: Chief Medical Officer	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Geoffrey M. Parker	director	15 RIORDAN PLACE, MENLO PARK CA 94025
Frank Karbe	director, officer: See Remarks	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David P Perry	director, 10 percent owner, officer: See Remarks	1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Andrew J. Armanino	director	C/O CALIFORNIA BANCORP, 1300 CLAY STREET, FIFTH FLOOR, OAKLAND CA 94612
Georgianna Maule-ffinch 2015 Trust	10 percent owner	C/O BETTER THERAPEUTICS, INC., 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Mark Heinen	officer: See Remarks	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Risa J Lavizzo-mourey	director	GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE ST., CHICAGO IL 60661
Kevin J Appelbaum	director, 10 percent owner, officer: Chief Executive Officer	4160 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Suying Liu	director	311 WEST 43RD STREET, 12TH FLOOR, NEW YORK NY 10036
Justin Zamirowski	officer: Chief Commercial Officer	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Kristin Wynholds	officer: Chief Product Officer	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Richard H Carmona	director	1221 BROADWAY, OAKLAND CA 94612
David P. Perry 2015 Trust	10 percent owner	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104